Cite
MLA Citation
Mark E. Robson et al.. “OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.” European journal of cancer, vol. 184, 2023, pp. 39–47. http://access.bl.uk/ark:/81055/vdc_100183610905.0x000023